CA2219948C - Chaine unique de gonadotrophines, adn les codant et methode de production - Google Patents

Chaine unique de gonadotrophines, adn les codant et methode de production Download PDF

Info

Publication number: CA2219948C
Authority: CA; Canada
Prior art keywords: subunit; beta; alpha; fsh; linker
Prior art date: 1994-02-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA2219948A

Other languages

English (en)

Other versions

CA2219948A1 (fr

Inventor

William R. Moyle

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Washington University in St Louis WUSTL

Original Assignee

Washington University in St Louis WUSTL

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-02-18

Filing date

1995-02-17

Publication date

2010-04-13

1995-02-17 Application filed by Washington University in St Louis WUSTL filed Critical Washington University in St Louis WUSTL

1995-02-17 Priority claimed from CA2183564A external-priority patent/CA2183564C/fr

1995-08-24 Publication of CA2219948A1 publication Critical patent/CA2219948A1/fr

2010-04-13 Application granted granted Critical

2010-04-13 Publication of CA2219948C publication Critical patent/CA2219948C/fr

2015-02-17 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

238000000034 method Methods 0.000 title abstract description 88
102000006771 Gonadotropins Human genes 0.000 title abstract description 59
108010086677 Gonadotropins Proteins 0.000 title abstract description 59
239000002622 gonadotropin Substances 0.000 title abstract description 59
229940094892 gonadotropins Drugs 0.000 title abstract description 17
108010073521 Luteinizing Hormone Proteins 0.000 abstract description 293
102000009151 Luteinizing Hormone Human genes 0.000 abstract description 290
229940040129 luteinizing hormone Drugs 0.000 abstract description 281
108090000623 proteins and genes Proteins 0.000 abstract description 172
102000004169 proteins and genes Human genes 0.000 abstract description 163
102000012673 Follicle Stimulating Hormone Human genes 0.000 abstract description 157
108010079345 Follicle Stimulating Hormone Proteins 0.000 abstract description 157
229940028334 follicle stimulating hormone Drugs 0.000 abstract description 150
230000000694 effects Effects 0.000 abstract description 149
229940088597 hormone Drugs 0.000 abstract description 111
239000005556 hormone Substances 0.000 abstract description 111
230000035558 fertility Effects 0.000 abstract description 107
108010062540 Chorionic Gonadotropin Proteins 0.000 abstract description 52
102000011022 Chorionic Gonadotropin Human genes 0.000 abstract description 52
102000003886 Glycoproteins Human genes 0.000 abstract description 35
108090000288 Glycoproteins Proteins 0.000 abstract description 35
239000011230 binding agent Substances 0.000 abstract description 30
241000124008 Mammalia Species 0.000 abstract description 26
238000004519 manufacturing process Methods 0.000 abstract description 22
230000004071 biological effect Effects 0.000 abstract description 21
230000002401 inhibitory effect Effects 0.000 abstract description 21
206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 abstract description 20
238000002360 preparation method Methods 0.000 abstract description 20
230000002829 reductive effect Effects 0.000 abstract description 19
230000003054 hormonal effect Effects 0.000 abstract description 13
230000004936 stimulating effect Effects 0.000 abstract description 13
230000002708 enhancing effect Effects 0.000 abstract description 8
229940084986 human chorionic gonadotropin Drugs 0.000 abstract description 5
239000003933 gonadotropin antagonist Substances 0.000 abstract description 2
235000018102 proteins Nutrition 0.000 description 150
230000027455 binding Effects 0.000 description 78
210000004027 cell Anatomy 0.000 description 58
108020004705 Codon Proteins 0.000 description 56
229940024606 amino acid Drugs 0.000 description 55
235000001014 amino acid Nutrition 0.000 description 55
230000015572 biosynthetic process Effects 0.000 description 55
150000001413 amino acids Chemical class 0.000 description 53
102000023108 LH Receptors Human genes 0.000 description 47
108010011942 LH Receptors Proteins 0.000 description 47
229940015047 chorionic gonadotropin Drugs 0.000 description 47
102000003864 Human Follicle Stimulating Hormone Human genes 0.000 description 44
108010082302 Human Follicle Stimulating Hormone Proteins 0.000 description 44
230000016087 ovulation Effects 0.000 description 43
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 42
238000011161 development Methods 0.000 description 40
230000018109 developmental process Effects 0.000 description 40
239000013598 vector Substances 0.000 description 40
125000003275 alpha amino acid group Chemical group 0.000 description 39
230000028327 secretion Effects 0.000 description 37
102000005962 receptors Human genes 0.000 description 35
108020003175 receptors Proteins 0.000 description 35
241000282414 Homo sapiens Species 0.000 description 32
230000001965 increasing effect Effects 0.000 description 30
108091026890 Coding region Proteins 0.000 description 28
238000013459 approach Methods 0.000 description 28
230000003472 neutralizing effect Effects 0.000 description 26
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 25
239000000427 antigen Substances 0.000 description 25
108091007433 antigens Proteins 0.000 description 25
102000036639 antigens Human genes 0.000 description 25
230000021595 spermatogenesis Effects 0.000 description 25
238000011282 treatment Methods 0.000 description 25
241001465754 Metazoa Species 0.000 description 24
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 24
239000013604 expression vector Substances 0.000 description 24
238000003556 assay Methods 0.000 description 23
230000006870 function Effects 0.000 description 23
238000006467 substitution reaction Methods 0.000 description 23
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 22
235000009582 asparagine Nutrition 0.000 description 22
230000002163 immunogen Effects 0.000 description 22
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 21
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 21
229960005309 estradiol Drugs 0.000 description 21
229930182833 estradiol Natural products 0.000 description 21
229960003604 testosterone Drugs 0.000 description 21
229960005486 vaccine Drugs 0.000 description 21
241000283690 Bos taurus Species 0.000 description 20
229940011871 estrogen Drugs 0.000 description 20
239000000262 estrogen Substances 0.000 description 20
108091008146 restriction endonucleases Proteins 0.000 description 20
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 19
108020004414 DNA Proteins 0.000 description 19
229960001230 asparagine Drugs 0.000 description 19
230000005764 inhibitory process Effects 0.000 description 19
230000009471 action Effects 0.000 description 18
239000003098 androgen Substances 0.000 description 18
238000012360 testing method Methods 0.000 description 18
230000003053 immunization Effects 0.000 description 17
108090000765 processed proteins & peptides Proteins 0.000 description 17
241000282412 Homo Species 0.000 description 16
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 16
230000013595 glycosylation Effects 0.000 description 16
238000006206 glycosylation reaction Methods 0.000 description 16
239000000047 product Substances 0.000 description 16
238000002649 immunization Methods 0.000 description 15
239000004471 Glycine Substances 0.000 description 14
108010076504 Protein Sorting Signals Proteins 0.000 description 14
230000007717 exclusion Effects 0.000 description 14
150000002482 oligosaccharides Polymers 0.000 description 14
230000035935 pregnancy Effects 0.000 description 14
238000012216 screening Methods 0.000 description 14
230000010009 steroidogenesis Effects 0.000 description 14
238000003786 synthesis reaction Methods 0.000 description 14
108091028043 Nucleic acid sequence Proteins 0.000 description 13
210000004246 corpus luteum Anatomy 0.000 description 13
238000013461 design Methods 0.000 description 13
239000012634 fragment Substances 0.000 description 13
230000028993 immune response Effects 0.000 description 13
208000000509 infertility Diseases 0.000 description 13
230000036512 infertility Effects 0.000 description 13
231100000535 infertility Toxicity 0.000 description 13
230000035772 mutation Effects 0.000 description 13
230000027758 ovulation cycle Effects 0.000 description 13
239000000243 solution Substances 0.000 description 13
241000894007 species Species 0.000 description 13
210000001550 testis Anatomy 0.000 description 13
241000700159 Rattus Species 0.000 description 12
230000002611 ovarian Effects 0.000 description 12
239000000186 progesterone Substances 0.000 description 12
229960003387 progesterone Drugs 0.000 description 12
210000002966 serum Anatomy 0.000 description 12
239000005557 antagonist Substances 0.000 description 11
238000006243 chemical reaction Methods 0.000 description 11
230000001939 inductive effect Effects 0.000 description 11
235000013930 proline Nutrition 0.000 description 11
102000053602 DNA Human genes 0.000 description 10
108060003951 Immunoglobulin Proteins 0.000 description 10
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 10
239000004473 Threonine Substances 0.000 description 10
239000000556 agonist Substances 0.000 description 10
125000000539 amino acid group Chemical group 0.000 description 10
210000002503 granulosa cell Anatomy 0.000 description 10
102000018358 immunoglobulin Human genes 0.000 description 10
238000001727 in vivo Methods 0.000 description 10
210000004698 lymphocyte Anatomy 0.000 description 10
210000004379 membrane Anatomy 0.000 description 10
239000012528 membrane Substances 0.000 description 10
239000000178 monomer Substances 0.000 description 10
239000008188 pellet Substances 0.000 description 10
201000010065 polycystic ovary syndrome Diseases 0.000 description 10
238000012163 sequencing technique Methods 0.000 description 10
238000010561 standard procedure Methods 0.000 description 10
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 9
239000002299 complementary DNA Substances 0.000 description 9
150000001875 compounds Chemical class 0.000 description 9
210000002332 leydig cell Anatomy 0.000 description 9
238000001243 protein synthesis Methods 0.000 description 9
230000014616 translation Effects 0.000 description 9
102000008175 FSH Receptors Human genes 0.000 description 8
108010060374 FSH Receptors Proteins 0.000 description 8
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 8
230000000890 antigenic effect Effects 0.000 description 8
239000000872 buffer Substances 0.000 description 8
230000007423 decrease Effects 0.000 description 8
230000011599 ovarian follicle development Effects 0.000 description 8
102000004196 processed proteins & peptides Human genes 0.000 description 8
241000588724 Escherichia coli Species 0.000 description 7
108020005038 Terminator Codon Proteins 0.000 description 7
241000251539 Vertebrata <Metazoa> Species 0.000 description 7
229940030486 androgens Drugs 0.000 description 7
229940046836 anti-estrogen Drugs 0.000 description 7
230000001833 anti-estrogenic effect Effects 0.000 description 7
229940124462 contraceptive vaccine Drugs 0.000 description 7
239000000328 estrogen antagonist Substances 0.000 description 7
230000008217 follicular development Effects 0.000 description 7
229940027941 immunoglobulin g Drugs 0.000 description 7
229940072221 immunoglobulins Drugs 0.000 description 7
238000002703 mutagenesis Methods 0.000 description 7
231100000350 mutagenesis Toxicity 0.000 description 7
229920001542 oligosaccharide Polymers 0.000 description 7
239000002245 particle Substances 0.000 description 7
230000004044 response Effects 0.000 description 7
239000007858 starting material Substances 0.000 description 7
239000000126 substance Substances 0.000 description 7
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 6
230000000903 blocking effect Effects 0.000 description 6
238000010367 cloning Methods 0.000 description 6
JGMOKGBVKVMRFX-HQZYFCCVSA-N dydrogesterone Chemical compound C1=CC2=CC(=O)CC[C@@]2(C)[C@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 JGMOKGBVKVMRFX-HQZYFCCVSA-N 0.000 description 6
229960004913 dydrogesterone Drugs 0.000 description 6
239000000833 heterodimer Substances 0.000 description 6
238000000338 in vitro Methods 0.000 description 6
210000004914 menses Anatomy 0.000 description 6
239000002773 nucleotide Substances 0.000 description 6
125000003729 nucleotide group Chemical group 0.000 description 6
230000008569 process Effects 0.000 description 6
238000002708 random mutagenesis Methods 0.000 description 6
150000003431 steroids Chemical class 0.000 description 6
108010057021 Menotropins Proteins 0.000 description 5
206010036049 Polycystic ovaries Diseases 0.000 description 5
241000288906 Primates Species 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
230000029087 digestion Effects 0.000 description 5
108020001507 fusion proteins Proteins 0.000 description 5
102000037865 fusion proteins Human genes 0.000 description 5
238000012544 monitoring process Methods 0.000 description 5
210000001672 ovary Anatomy 0.000 description 5
230000009467 reduction Effects 0.000 description 5
239000012064 sodium phosphate buffer Substances 0.000 description 5
210000002700 urine Anatomy 0.000 description 5
238000002255 vaccination Methods 0.000 description 5
102220547697 Carcinoembryonic antigen-related cell adhesion molecule 3_L73T_mutation Human genes 0.000 description 4
102000014914 Carrier Proteins Human genes 0.000 description 4
206010062767 Hypophysitis Diseases 0.000 description 4
241000700605 Viruses Species 0.000 description 4
125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 4
150000001508 asparagines Chemical class 0.000 description 4
150000001720 carbohydrates Chemical group 0.000 description 4
230000008878 coupling Effects 0.000 description 4
238000010168 coupling process Methods 0.000 description 4
238000005859 coupling reaction Methods 0.000 description 4
210000003527 eukaryotic cell Anatomy 0.000 description 4
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
125000000404 glutamine group Chemical class N[C@@H](CCC(N)=O)C(=O)* 0.000 description 4
XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 4
-1 hCG Proteins 0.000 description 4
230000006698 induction Effects 0.000 description 4
230000003993 interaction Effects 0.000 description 4
230000029849 luteinization Effects 0.000 description 4
239000000203 mixture Substances 0.000 description 4
238000002823 phage display Methods 0.000 description 4
230000001817 pituitary effect Effects 0.000 description 4
210000003635 pituitary gland Anatomy 0.000 description 4
229920001184 polypeptide Polymers 0.000 description 4
230000002028 premature Effects 0.000 description 4
102220024935 rs199473369 Human genes 0.000 description 4
230000019491 signal transduction Effects 0.000 description 4
230000009870 specific binding Effects 0.000 description 4
230000000638 stimulation Effects 0.000 description 4
239000001226 triphosphate Substances 0.000 description 4
235000011178 triphosphate Nutrition 0.000 description 4
125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 4
108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
108010073583 AGCGCT-specific type II deoxyribonucleases Proteins 0.000 description 3
241000282693 Cercopithecidae Species 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 3
102000018997 Growth Hormone Human genes 0.000 description 3
108010051696 Growth Hormone Proteins 0.000 description 3
108091006905 Human Serum Albumin Proteins 0.000 description 3
102000008100 Human Serum Albumin Human genes 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
108010002747 Pfu DNA polymerase Proteins 0.000 description 3
240000004808 Saccharomyces cerevisiae Species 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 3
239000007983 Tris buffer Substances 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000037396 body weight Effects 0.000 description 3
210000004899 c-terminal region Anatomy 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
229940088598 enzyme Drugs 0.000 description 3
229940035638 gonadotropin-releasing hormone Drugs 0.000 description 3
239000000122 growth hormone Substances 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
230000000938 luteal effect Effects 0.000 description 3
230000035800 maturation Effects 0.000 description 3
238000005259 measurement Methods 0.000 description 3
230000009245 menopause Effects 0.000 description 3
230000036961 partial effect Effects 0.000 description 3
238000003752 polymerase chain reaction Methods 0.000 description 3
239000013641 positive control Substances 0.000 description 3
239000002243 precursor Substances 0.000 description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
238000003127 radioimmunoassay Methods 0.000 description 3
210000001685 thyroid gland Anatomy 0.000 description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
239000004475 Arginine Substances 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
108010078791 Carrier Proteins Proteins 0.000 description 2
102000008186 Collagen Human genes 0.000 description 2
108010035532 Collagen Proteins 0.000 description 2
238000001712 DNA sequencing Methods 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
108010028837 GTGCAC-specific type II deoxyribonucleases Proteins 0.000 description 2
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
206010035226 Plasma cell myeloma Diseases 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
241000283984 Rodentia Species 0.000 description 2
102000011923 Thyrotropin Human genes 0.000 description 2
108010061174 Thyrotropin Proteins 0.000 description 2
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
210000004198 anterior pituitary gland Anatomy 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
108010066058 beta Subunit Luteinizing Hormone Proteins 0.000 description 2
108091008324 binding proteins Proteins 0.000 description 2
230000008512 biological response Effects 0.000 description 2
229940098773 bovine serum albumin Drugs 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
239000013553 cell monolayer Substances 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
229920001436 collagen Polymers 0.000 description 2
230000001276 controlling effect Effects 0.000 description 2
239000013078 crystal Substances 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
230000002124 endocrine Effects 0.000 description 2
239000000284 extract Substances 0.000 description 2
230000003325 follicular Effects 0.000 description 2
238000002523 gelfiltration Methods 0.000 description 2
210000004408 hybridoma Anatomy 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
230000003278 mimic effect Effects 0.000 description 2
201000000050 myeloid neoplasm Diseases 0.000 description 2
239000013642 negative control Substances 0.000 description 2
230000009125 negative feedback regulation Effects 0.000 description 2
238000006386 neutralization reaction Methods 0.000 description 2
230000003169 placental effect Effects 0.000 description 2
239000000583 progesterone congener Substances 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000010076 replication Effects 0.000 description 2
230000001850 reproductive effect Effects 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
238000010187 selection method Methods 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
150000003588 threonines Chemical class 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
230000001052 transient effect Effects 0.000 description 2
239000004474 valine Substances 0.000 description 2
238000005406 washing Methods 0.000 description 2
DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
VSPHTALXUBRJFB-PXFSOSDPSA-N 2-aminoacetic acid (2S)-2-amino-3-hydroxypropanoic acid Chemical compound NCC(O)=O.NCC(O)=O.NCC(O)=O.NCC(O)=O.NCC(O)=O.NCC(O)=O.OC[C@H](N)C(O)=O.OC[C@H](N)C(O)=O.OC[C@H](N)C(O)=O.OC[C@H](N)C(O)=O.OC[C@H](N)C(O)=O.OC[C@H](N)C(O)=O VSPHTALXUBRJFB-PXFSOSDPSA-N 0.000 description 1
ZVEUWSJUXREOBK-DKWTVANSSA-N 2-aminoacetic acid;(2s)-2-amino-3-hydroxypropanoic acid Chemical group NCC(O)=O.OC[C@H](N)C(O)=O ZVEUWSJUXREOBK-DKWTVANSSA-N 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
108010032595 Antibody Binding Sites Proteins 0.000 description 1
101100107610 Arabidopsis thaliana ABCF4 gene Proteins 0.000 description 1
101100124472 Caenorhabditis elegans hlh-13 gene Proteins 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
102000029816 Collagenase Human genes 0.000 description 1
108060005980 Collagenase Proteins 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
241000701959 Escherichia virus Lambda Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
108010033155 GGGCCC-specific type II deoxyribonucleases Proteins 0.000 description 1
BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
241000282567 Macaca fascicularis Species 0.000 description 1
241000422980 Marietta Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
108010021466 Mutant Proteins Proteins 0.000 description 1
102000008300 Mutant Proteins Human genes 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
241000609499 Palicourea Species 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
108010076039 Polyproteins Proteins 0.000 description 1
208000002500 Primary Ovarian Insufficiency Diseases 0.000 description 1
239000004365 Protease Substances 0.000 description 1
230000010799 Receptor Interactions Effects 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
101100068078 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GCN4 gene Proteins 0.000 description 1
108010008038 Synthetic Vaccines Proteins 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
206010000210 abortion Diseases 0.000 description 1
231100000176 abortion Toxicity 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
230000009833 antibody interaction Effects 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
230000001593 cAMP accumulation Effects 0.000 description 1
230000003915 cell function Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
229960002424 collagenase Drugs 0.000 description 1
230000037029 cross reaction Effects 0.000 description 1
238000012258 culturing Methods 0.000 description 1
230000001351 cycling effect Effects 0.000 description 1
108010075496 deglycosylated HCG Proteins 0.000 description 1
108700003318 deglycosylated luteinizing hormone Proteins 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000007865 diluting Methods 0.000 description 1
239000000539 dimer Substances 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
210000005081 epithelial layer Anatomy 0.000 description 1
JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 description 1
230000012173 estrus Effects 0.000 description 1
230000029142 excretion Effects 0.000 description 1
230000006408 female gonad development Effects 0.000 description 1
230000004720 fertilization Effects 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
150000002333 glycines Chemical class 0.000 description 1
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
210000002149 gonad Anatomy 0.000 description 1
230000002710 gonadal effect Effects 0.000 description 1
229940121381 gonadotrophin releasing hormone (gnrh) antagonists Drugs 0.000 description 1
230000012010 growth Effects 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
239000003668 hormone analog Substances 0.000 description 1
108091008039 hormone receptors Proteins 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
239000012133 immunoprecipitate Substances 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
208000021267 infertility disease Diseases 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
238000002372 labelling Methods 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
244000144972 livestock Species 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000003563 lymphoid tissue Anatomy 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000002175 menstrual effect Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
102000035118 modified proteins Human genes 0.000 description 1
108091005573 modified proteins Proteins 0.000 description 1
229940126619 mouse monoclonal antibody Drugs 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
210000000287 oocyte Anatomy 0.000 description 1
210000004681 ovum Anatomy 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
239000006174 pH buffer Substances 0.000 description 1
238000004091 panning Methods 0.000 description 1
229940055729 papain Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
239000006187 pill Substances 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
229940063238 premarin Drugs 0.000 description 1
206010036601 premature menopause Diseases 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000006259 progesterone secretion Effects 0.000 description 1
150000003148 prolines Chemical class 0.000 description 1
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
230000000541 pulsatile effect Effects 0.000 description 1
239000000376 reactant Substances 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
230000027272 reproductive process Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000000630 rising effect Effects 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
210000000717 sertoli cell Anatomy 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
238000002764 solid phase assay Methods 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
238000013223 sprague-dawley female rat Methods 0.000 description 1
239000003270 steroid hormone Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
229960000874 thyrotropin Drugs 0.000 description 1
230000001748 thyrotropin Effects 0.000 description 1
238000004448 titration Methods 0.000 description 1
238000006257 total synthesis reaction Methods 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
210000002993 trophoblast Anatomy 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
241000712461 unidentified influenza virus Species 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000002023 wood Substances 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1

Landscapes

Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

CA2219948A 1994-02-18 1995-02-17 Chaine unique de gonadotrophines, adn les codant et methode de production Expired - Lifetime CA2219948C (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US19938294A	1994-02-18	1994-02-18
US08/199,382		1994-02-18
CA2183564A CA2183564C (fr)	1994-02-18	1995-02-17	Procedes de modification de la fecondite

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2183564A Division CA2183564C (fr)	1994-02-18	1995-02-17	Procedes de modification de la fecondite

Publications (2)

Publication Number	Publication Date
CA2219948A1 CA2219948A1 (fr)	1995-08-24
CA2219948C true CA2219948C (fr)	2010-04-13

Family

ID=25678626

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2219948A Expired - Lifetime CA2219948C (fr)	1994-02-18	1995-02-17	Chaine unique de gonadotrophines, adn les codant et methode de production

Country Status (1)

Country	Link
CA (1)	CA2219948C (fr)

1995
- 1995-02-17 CA CA2219948A patent/CA2219948C/fr not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA2219948A1 (fr)	1995-08-24

Legal Events

Date	Code	Title	Description
2000-05-15	EEER	Examination request
2015-04-21	MKEX	Expiry	Effective date: 20150217

Publication	Publication Date	Title
AU695111B2 (en)	1998-08-06	Methods for altering fertility
US6242580B1 (en)	2001-06-05	Single-chain forms of the glycoprotein hormone quartet
US10584166B2 (en)	2020-03-10	Ligands that potentiate the bioactivity of gonadotropins
JP2002204698A (ja)	2002-07-23	精巣−特異的インシュリン同族体ポリペプチド
JP3330373B2 (ja)	2002-09-30	変容免疫学的特性、性能および／またはレセプター特異性を有する糖タンパク質ホルモンの類似体
CN103328510B (zh)	2016-01-06	促黄体素配体和配体-促性腺素复合物
CA1057742A (fr)	1979-07-03	Polypeptides modifies servant d'antigenes
WO1988007547A1 (fr)	1988-10-06	Molecules biologiquement actives
US6486303B1 (en)	2002-11-26	Method for making hormone heterodimers
AU723853B2 (en)	2000-09-07	Methods for altering fertility
AU701702B2 (en)	1999-02-04	Modified human chorionic (beta-hCG) proteins and their medical use
Thanavala et al.	1980	Affinity, cross-reactivity and biological effectiveness of rabbit antibodies against a synthetic 37 amino acid C-terminal peptide of human chorionic gonadotrophin
Lund et al.	1998	Immunological analysis of epitopes on hCG
CA1085383A (fr)	1980-09-09	Modification antigenique de polypeptides
JP2003535021A (ja)	2003-11-25	抗体ワクチン避妊薬
Cosowsky	1996	Use of human chorionic gonadotropin/bovine luteinizing hormone beta-subunit chimeras to define an epitope and localize determinants for receptor binding
Hasegawa et al.	1999	Evaluation of the contraceptive potential of recombinant proteins and synthetic peptides of zona pellucida (ZP)
Ehrlich et al.	1998	Epitope-specific focusing of the immune response to a minimized human chorionic gonadotropin analog